FutureMeds Named Finalist for 2026 SCRS Excellence in Patient Centricity Award

FutureMeds has been recognised for its sustained work to preserve safe, responsible access to clinical research in Ukraine.

FutureMeds has been named a finalist for the 2026 SCRS Excellence in Patient Centricity Award.

The award recognises clinical research sites that place patient needs and experiences at the centre of how studies are planned and delivered.

FutureMeds’ entry focuses on what this has required in Ukraine since 2022.

When patient centricity changed meaning

FutureMeds entered Ukraine through established research sites in Kyiv and Zhytomyr in December 2021.

Only weeks later, the operating environment changed almost completely.

A planned visit could become a decision about personal safety, transport, communication or whether a participant had been displaced. Established processes had to be reconsidered against changing circumstances.

The immediate priority was to determine the safest and most appropriate path for each person, within the study protocol and with respect for their wishes.

“The objective was to understand risks at site and study level, communicate them transparently and protect the opportunity for patients to be considered where delivery remained responsible.”

— Dr Ivan Vyshnyvetskyy, Managing Director at FutureMeds Ukraine

From continuity to preserving access

Supporting existing participants was only the first challenge.

Without operational sites and experienced research professionals, new studies would have fewer credible places to open. Over time, that would reduce the research opportunities available to Ukrainian patients.

FutureMeds chose to remain and continue investing. The company added a site in Vinnytsia in 2023. In 2025, we partnered with Sheptytsky Hospital to establish a fourth, hospital-based location in Lviv.

The work has involved supporting local teams, maintaining clinical relationships and preserving the infrastructure required for appropriate studies to return.

A patient cannot consider a clinical trial that never opens in their country. Keeping research capacity in place helps preserve that choice.

Assessing risk using current evidence

FutureMeds has not asked sponsors to overlook the realities of conducting clinical research during a war.

Our team's role has been to provide current information about site capabilities, patient populations and operational safeguards. This enables sponsors and CROs to assess a particular study and location using available evidence rather than geography alone.

Responsible inclusion means understanding risks, identifying what can be controlled and making informed decisions at study and site level.

That same discipline supports both patient protection and reliable study delivery.

Part of a wider effort

FutureMeds does not claim to have preserved clinical research in Ukraine alone. We operate as part of the local research ecosystem.

Patients, investigators, hospitals, regulators, ethics committees, sponsors, CROs and logistics providers have all contributed to keeping the country’s research infrastructure functioning under sustained pressure.

The finalist recognition reflects the work of FutureMeds’ Ukrainian colleagues within that wider effort. Our teams continue to make careful, patient-by-patient decisions in circumstances no conventional continuity plan could fully anticipate.

The award recipient will be announced at the SCRS Global Site Solutions Summit in Orlando on October 17.